Kochi, Dec 1: CARe Keralam, a common facility centre set up as a joint venture between Ayurveda units and the Kerala Government, will identify 20 popular formulations for scientific validation with a view to ensuring wider acceptability for Ayurvedic medicines which are now marketed mostly as food supplements.
CARe Keralam (the Confederation of Ayurvedic Renaissance Keralam Ltd) will be supported by the National Innovation Council and the Council for Scientific and Industrial Research (CSIR) in this attempt to give international recognition to Ayurvedic medicines.
CARe Keralam recently scientifically validated the anti-diabetes formulation Nishaakathakaadhi kashayam (NKK), in a first-of-its-kind attempt in the history of Ayurveda, facilitating companies to sell this product as a drug abroad. The comprehensive dossier was released at a function in Delhi on Saturday.
“We have been entrusted to do this pioneering scientific study by the National Innovation Council. We are ready to take up more such studies to promote the standardization of Ayurveda products on a par with modern medicines,” CARe Keralam managing director Shri Karimpuzha Raman said.
CARe Keralam, along with CSIR and other national agencies, is also planning a grand Ayurveda summit to place this age-old Indian system of medicine into limelight and identify the key products for scientific validation with the support of the industry.
Spurred by the huge response to its dossier on NKK, the group is also planning to hold a clinical trial of the formulation with a minimum 500 subjects to establish the efficacy and safety of the product and officially declare it as a safe medicine as per global standards.
CARe Keralam, a Common Facility Center established in Koratty in Thrissur district of Kerala, with the support of the AYUSH department, Govt. of India, conducted a comprehensive multidisciplinary study on the NKK’s eight raw materials, and the Ayurvedic product formulated from them, demonstrating its efficacy and toxicity on rats.
The dossier contains quality control parameters for the medicine’s ingredients, product profile, manufacturing process, toxicity studies, and anti-diabetic activity in rats with Streptzotocin-induced diabetes. In addition, it also contains formats for regulatory submission, drug licencing and GMP certification.
While releasing the dossier, NIC chairman and scientific advisor to the PM, Shri Sam Pitroda said the need of the hour was to bring traditional knowledge to the mainstream through proper documentation and integrate them with modern medicines to make the treatment accessible and affordable.